Israel study: 4th vaccine shows limited results with omicron

Israel study: 4th vaccine shows limited results with omicron
Siblings wait to receive the COVID-19 vaccine at Clalit Health Services in Mevaseret Zion, Tuesday, Jan. 11, 2022. Credit: AP Photo/Maya Alleruzzo

An Israeli hospital on Monday said preliminary research indicates a fourth dose of the coronavirus vaccine provides only limited defense against the omicron variant that is raging around the world.

Sheba Hospital last month began administering a fourth vaccine to more than 270 medical workers—154 who received a Pfizer-BioNtech vaccine and 120 others who received Moderna's. All had previously been vaccinated three times with the Pfizer-BioNtech vaccine.

The clinical trial found that both groups showed increases in antibodies "slightly higher" than following the third vaccine last year. But it said the increased antibodies did not prevent the spread of omicron.

"Despite increased antibody levels, the fourth vaccine only offers a partial defense against the virus," said Dr. Gili Regev-Yochay, director of the hospital's infection disease unit. "The vaccines, which were more effective against previous variants, offer less protection versus omicron."

The preliminary results raised questions about Israel's decision to offer a second shot—and fourth overall—to its over-60 population. The government says over 500,000 people have received the second booster in recent weeks.

Dr. Nahman Ash, director of Israel's Health Ministry, said the research did not mean the fourth effort was a mistake. "It returns the level of antibodies to what it was at the beginning of the third booster. That has great importance, especially among the older population," he told Channel 13 TV.

Israel study: 4th vaccine shows limited results with omicron
N'amah Yetzhak Abohaikal, a volunteer with the women's unit of United Hatzalah emergency service, prepares administer the COVID-19 vaccine to a teen girl as her brother and grandmother watch, at Clalit Health Services in Mevaseret Zion, Tuesday, Jan. 11, 2022. Credit: AP Photo/Maya Alleruzzo

But he said the research would be taken into account as authorities debate whether to expand the additional booster campaign to the broader population.

Israel was one of the first countries last year to widely vaccinate its population and last summer became the first to offer a booster shot. The latest booster campaign for older Israelis also is believed to be the first of its kind in the world.

Israel's aggressive vaccination efforts have not been able to stop an outbreak in recent weeks. The variant has caused record-setting infection levels and sent a growing number of people to the hospital, though the numbers of seriously ill remain below previous waves.

It has also forced large numbers of Israelis into quarantine, straining schools and businesses.

Omicron is already dominant in many countries and can also infect those who have been vaccinated or had previously been infected by prior versions of the virus. Early studies, however, show it is less likely to cause than the previous delta variant. Vaccination and a booster still offer strong protection from serious illness, hospitalization and death.

On Tuesday, the Israeli government said it was shortening the mandatory quarantine period from seven days to five days in order to help keep the economy running.

"This decision will enable us to continue safeguarding on the one hand and to keep the economy going at this time on the other, even though it is difficult, so that we can get through this wave safely," said Prime Minister Naftali Bennett.


Explore further

Israeli hospital starts 4th jab trial as ministry weighs rollout

© 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Citation: Israel study: 4th vaccine shows limited results with omicron (2022, January 17) retrieved 22 May 2022 from https://medicalxpress.com/news/2022-01-israel-4th-vaccine-limited-results.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
275 shares

Feedback to editors